0001479290-21-000173.txt : 20211215
0001479290-21-000173.hdr.sgml : 20211215
20211215201719
ACCESSION NUMBER: 0001479290-21-000173
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211213
FILED AS OF DATE: 20211215
DATE AS OF CHANGE: 20211215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Russell Angus C.
CENTRAL INDEX KEY: 0001534002
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 211495582
MAIL ADDRESS:
STREET 1: C/O INTERMUNE, INC.
STREET 2: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wf-form4_163961742195547.xml
FORM 4
X0306
4
2021-12-13
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001534002
Russell Angus C.
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2021-12-13
4
P
0
6400
15.7408
A
26913
D
The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.65 to $15.81. Mr. Russell undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
/s/ Gordon Ho, Attorney-in-Fact
2021-12-15